KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - OtherShares OutstandingShares Outstanding
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (IS) (2016 - 2026)

TherapeuticsMD filings provide 14 years of Depreciation & Amortization (IS) readings, the most recent being $94000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (IS) fell 1.05% to $94000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $383000.0, a 18.68% decrease, with the full-year FY2025 number at $384000.0, down 24.56% from a year prior.
  • Depreciation & Amortization (IS) hit $94000.0 in Q1 2026 for TherapeuticsMD, down from $97000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $637000.0 in Q4 2023 to a low of $27000.0 in Q1 2023.
  • Median Depreciation & Amortization (IS) over the past 4 years was $97000.0 (2025), compared with a mean of $146846.2.
  • The widest YoY moves for Depreciation & Amortization (IS): up 392.59% in 2024, down 84.3% in 2024.
  • TherapeuticsMD's Depreciation & Amortization (IS) stood at $637000.0 in 2023, then plummeted by 84.3% to $100000.0 in 2024, then decreased by 3.0% to $97000.0 in 2025, then fell by 3.09% to $94000.0 in 2026.
  • The last three reported values for Depreciation & Amortization (IS) were $94000.0 (Q1 2026), $97000.0 (Q4 2025), and $96000.0 (Q3 2025) per Business Quant data.